Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

被引：0
作者：
Alessi, Joao Victor Machado
Ricciuti, Biagio
Aguilar, Elizabeth Jimenez
Hong, Fangxin
Wei, Zihan
Nishino, Mizuki
Plodkowski, Andrew J.
Sawan, Peter
Luo, Jia
Rizvi, Hira
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Biostat Core, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9568
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
    Roboubi, Amytis
    Wasielewski, Eric
    Bordier, Soraya
    Turlotte, Amelie
    Pavaut, Geoffrey
    Scherpereel, Arnaud
    Cortot, Alexis
    Gauvain, Clement
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [42] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Dolores Isla
    Marta Lopez-Brea
    María Espinosa
    Natalia Arrabal
    Diego Pérez-Parente
    David Carcedo
    Reyes Bernabé-Caro
    Cost Effectiveness and Resource Allocation, 21
  • [43] A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer
    Nogami, Naoyuki
    Umemura, Shigeki
    Kozuki, Toshiyuki
    Zenke, Yoshitaka
    Ohtani, Junko
    Ishii, Mikio
    Han, Shirong
    Noguchi, Kazuo
    Horinouchi, Hidehito
    RESPIRATORY INVESTIGATION, 2025, 63 (03) : 296 - 302
  • [44] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [45] PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
    Majem, Margarita
    Cobo, Manuel
    Isla, Dolores
    Marquez-Medina, Diego
    Rodriguez-Abreu, Delvys
    Casal-Rubio, Joaquin
    Moran-Bueno, Teresa
    Bernabe-Caro, Reyes
    Perez-Parente, Diego
    Ruiz-Gracia, Pedro
    Arroyo, Marta Marina
    Paz-Ares, Luis
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [46] Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
    Zhijie Xu
    Xiang Wang
    Xi Chen
    Shuangshuang Zeng
    Zhicheng Gong
    Yuanliang Yan
    Journal of Cell Communication and Signaling, 2020, 14 : 129 - 130
  • [47] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Isla, Dolores
    Lopez-Brea, Marta
    Espinosa, Maria
    Arrabal, Natalia
    Perez-Parente, Diego
    Carcedo, David
    Bernabe-Caro, Reyes
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [48] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [49] Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
    Jimenez Galan, Rocio
    Prado-Mel, Elena
    Antonia Perez-Moreno, Maria
    Caballano-Infantes, Estefania
    Flores Moreno, Sandra
    BIOLOGY-BASEL, 2021, 10 (09):
  • [50] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
12345